ClinicalTrials.gg
CompletedNCT06310616Updated Dec 10, 2024

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

A Phase 1 interventional study of VH4524184 and Loestrin in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
167th of 210
26 · median 82
Started
2024
with 10 others
Phase 1
83 of 266
9 open now
Registered
245th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 167th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2024, is one of 83 in phase 1, and was the 245th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study aims to assess any impact of VH4524184 on the pharmacokinetic (PK) profile of an ethinyl estradiol (EE) and norethindrone acetate (NEA) containing oral contraceptive (OC) administered to healthy adult female participants.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV
  • Oral contraceptive
  • Pharmacokinetic
  • Ethinyl estradiol
  • Norethindrone acetate
  • Potential drug-drug interaction
  • Healthy adult female participants
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants 18 to 45 years of age
  • POCBP with intact ovarian function by medical history and history of regular menstrual cycles for the past 12
  • Body weight greater than or equal to (≥) 45 kilograms (kg) and (BMI) within the range of 18.5 to 32.0 kg/m2
  • Female participants of must use approved highly effective non-hormonal forms of .
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs.
  • Lymphoma, leukemia, or any within the past 5 years with some exceptions
  • Breast cancer or in remission within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities with some exceptions.
  • Any personal and/or family history of thrombophilia or blood clots
  • Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long syndrome.
  • History of seizure(s).
  • Any known or suspected pre-existing psychiatric condition, including depression, anxiety, and/or insomnia/sleep disturbances.
  • Subjects with history of drug , delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions will be excluded.
  • Participant is mentally or legally incapacitated.

Prior/Concomitant Therapy

  • Any warnings and that apply based on Loestrin prescribing information.

Prior/Concurrent Clinical Study Experience

  • Exposure to more than 4 new products (including long-acting investigational products) within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent (or screening) any other clinical study.
  • Participant has donated or lost blood (>500 millilitres (mL)) or blood products within 2 months (56-day period) prior to Day -1 admission or has donated plasma within 30 days prior to first OC administration.
  • Current enrollment or past participation in this clinical study. Unwillingness or inability to follow the procedures outlined in the protocol.
  • Positive 1 (HIV-1) antibody test.
  • Pregnant at screening) or lactating.
  • POCBP who are unwilling or unable to use an appropriate non-hormonal method of highly effective from at least Day 1 of Treatment Period 1 until 14 days after the last dose of VH4524184.
  • Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >7 units for females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Regular use of known drugs of abuse.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Loestrin + VH4524184

    Eligible participants entering a run-in period of 21 days (Days -28 through -8) will receive Loestrin (EE and NEA) to stabilize on the combined OCs containing EE and NEA to synchronize the menstrual cycles of multiple participants. Participants completing the run-in period will enter Treatment Period 1 and will be administered Loestrin once daily from Days 1 to 10. On Day 11, participants will enter Treatment Period 2 and will be administered Loestrin + VH4524184 once daily from Days 11 to 20.

    Drug: VH4524184 · Drug: Loestrin

Interventions

  • VH4524184 will be administered.

  • DrugLoestrin

    Loestrin will be administered.

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) from time zero (pre-dose) to the end of the dosing interval at steady state (AUC0-Tau, ss) of EE and NEA without coadministration with VH4524184

    Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis.

    Time frame: On Day 10

  2. AUC0-Tau, ss of EE and NEA with coadministration with VH4524184

    Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis.

    Time frame: On Day 20

  3. Maximum plasma concentration (Cmax) for EE and NEA without coadministration with VH4524184

    Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis.

    Time frame: On Day 10

  4. Cmax for EE and NEA with coadministration with VH4524184

    Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis.

    Time frame: On Day 20

Secondary outcomes

  1. Number of participants with adverse events (AEs) and severity of AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From Day -28 (Run-In-Period) up to approximately 2 months (Day 28 +/- 3 days)

  2. Number of participants with AEs leading to discontinuation of study intervention

    Time frame: Throughout the study treatment period (from Day -28 up to Day 20)

  3. Change from baseline of liver panel laboratory parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ASP) (International units per liter)

    Time frame: Baseline (Day -28) up to Day 21

  4. Change from baseline of liver panel laboratory parameters: Total bilirubin, Direct bilirubin (Micromoles per liter [umol/L])

    Time frame: Baseline (Day -28) up to Day 21

  5. Change from baseline of liver panel laboratory parameters: International normalized ratio (INR) (Ratio)

    Time frame: Baseline (Day -28) up to Day 21

  6. Number of participants with maximum toxicity grade increase from baseline of liver panel laboratory parameters: ALT, AST, alkaline phosphatase, total bilirubin, Direct bilirubin, and INR

    Time frame: Baseline (Day -28) up to Day 21

  7. Maximum plasma concentration at steady state (Cmax,ss) for VH4524184

    Blood samples will be collected at indicated timepoint for plasma VH4524184 PK analysis.

    Time frame: On Day 20

  8. Time to maximum concentration at steady state (Tmax, ss) during dosing interval for VH4524184

    Blood samples will be collected at indicated timepoint for plasma VH4524184 PK analysis.

    Time frame: On Day 20

  9. Area under the concentration-time curve from time zero(pre-dose) to the end of the dosing interval at steady state (AUC0-Tau, ss) for VH4524184

    Blood samples will be collected at indicated timepoint for plasma VH4524184 PK analysis.

    Time frame: On Day 20

  10. Trough concentration prior to the next dose (Ctrough) for VH4524184

    Blood samples will be collected at indicated timepoints for plasma VH4524184 PK analysis.

    Time frame: On Day 12, Day 16, and Day 20

07

Study locations

1 site
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2024, 5 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 5 months is close to that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 15, 2024
StartActual
Mar 6, 2024
Primary completionActual
Aug 15, 2024
CompletionActual
Aug 15, 2024
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06310616
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Mar 6, 2024
Primary completion
Aug 15, 2024
Completion
Aug 15, 2024
Last update
Dec 10, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH4524184

Start the discussion